$1.2bn J&J deceptive marketing fine overturned


The Arkansas Supreme Court has overturned a lower court’s fine of $1.2 billion (£725 million), imposed on Johnson & Johnson’s subsidiary Janssen in April 2012 over its marketing of antipsychotic drug Risperdal (risperidone).

The state of Arkansas’s case against Janssen revolves around its handling of a request by the US Food and Drug Administration (FDA) to inform doctors of possible side effects of the whole class of atypical antipsychotics, to which risperidone belongs. Briefly, the case contends that Janssen misled doctors about the safety of risperidone relative to other drugs, causing them to prescribe it favourably. Since many of these prescriptions were paid for by the US Medicaid scheme for helping poor patients afford drugs, Arkansas claims the company defrauded the state.

In part, the fine was overturned because the Supreme Court decided that law that the State was accusing Janssen of contravening applies to healthcare institutions, not pharmaceutical companies. Janssen is awaiting a ruling in South Carolina over similar allegations, and a similar case in Louisiana was overturned in January. None of these cases are related to the J&J’s $2.2 billion fine from a federal case brought by the US Department of Justice over mismarketing of Risperdal.


Related Content

Weathering the storm

6 January 2014 Business

news image

Pharmaceutical industry roundup 2013

Judge slashes fines in drug safety case

29 October 2014 Business

news image

Takeda and Eli Lilly’s $9 billion damages in diabetes trial reduced to $38 million

Most Read

Higher levels of some metals in e-cigarette smoke

8 September 2014 Research

news image

Scientists call for regulators to help clear smoke and mirrors surrounding vaping safety

Isotope effect produces new type of chemical bond

22 October 2014 Research

news image

Evidence emerges for vibrational bond first proposed 30 years ago

Most Commented

Higher levels of some metals in e-cigarette smoke

8 September 2014 Research

news image

Scientists call for regulators to help clear smoke and mirrors surrounding vaping safety

US agency fast-tracks Ebola vaccine development

23 October 2014 News and Analysis

news image

Health and Human Services invests almost $6 million to ready an Ebola vaccine candidate for clinical trials, meanwhile GSK sa...